Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer

Results from JMTO LC 0004

Shun Ichi Isa, Tomoya Kawaguchi, Satoshi Teramukai, Koichi Minato, Yoshinobu Ohsaki, Kazuhiko Shibata, Toshirou Yonei, Kenji Hayashibara, Masanori Fukushima, Masaaki Kawahara, Kiyoyuki Furuse, Philip Mack

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

BACKGROUND: The Japan-Multinational Trial Organization (JMTO) lung cancer (LC) 0003 was a prospective randomized phase III trial investigating advanced non-small cell lung cancer comparing paclitaxel (P) plus carboplatin (C) versus vinorelbine (V), gemcitabine (G) followed by docetaxel (D). This trial was conducted with Southwest Oncology Group (SWOG) 0003 using a common arm of PC. An analysis of SWOG 0003 samples showed that low osteopontin (OPN) plasma levels were highly prognostic for a better outcome. We performed an independent investigation to validate these results using samples from Japanese patients enrolled in the JMTO LC 0004, a correlative study associated with JMTO LC 0003. METHODS: A total of 20 ml of blood was collected before treatment from patients enrolled in JMTO LC 0003. Serum concentrations of OPN and basic fibroblast growth factor (bFGF) were measured by enzyme-linked immunosorbent assay. Effects of OPN and bFGF levels on tumor response, progression-free survival (PFS), and overall survival (OS) were examined. RESULTS: Seventy-one samples were obtained, including 32 specimens from the PC arm and 39 from the VGD arm. There were no significant relationships between either OPN or bFGF levels with patient characteristics. In an analysis of clinical outcome, low OPN levels correlated with better OS and progression-free survival (hazard ratio [HR] = 0.57; 95% confidence interval [CI], 0.33-0.97; p = 0.037, HR = 0.42; 95% CI, 0.25-0.70; p = 0.001, respectively) and high bFGF levels correlated with better OS (HR = 0.53; 95% CI, 0.31-0.90; p = 0.018). CONCLUSION: Consistent with the findings from SWOG 0003, low OPN serum levels were significantly associated with a favorable prognosis in the JMTO LC 0004. Additionally, high bFGF levels were associated with improved survival.

Original languageEnglish (US)
Pages (from-to)1104-1110
Number of pages7
JournalJournal of Thoracic Oncology
Volume4
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Osteopontin
Non-Small Cell Lung Carcinoma
Fibroblast Growth Factor 2
Lung Neoplasms
Japan
Organizations
Survival
Serum
docetaxel
Confidence Intervals
gemcitabine
Disease-Free Survival
Carboplatin
Paclitaxel
Enzyme-Linked Immunosorbent Assay
Neoplasms

Keywords

  • BFGF
  • Correlative study
  • Non-small cell lung cancer
  • Osteopontin

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer : Results from JMTO LC 0004. / Isa, Shun Ichi; Kawaguchi, Tomoya; Teramukai, Satoshi; Minato, Koichi; Ohsaki, Yoshinobu; Shibata, Kazuhiko; Yonei, Toshirou; Hayashibara, Kenji; Fukushima, Masanori; Kawahara, Masaaki; Furuse, Kiyoyuki; Mack, Philip.

In: Journal of Thoracic Oncology, Vol. 4, No. 9, 09.2009, p. 1104-1110.

Research output: Contribution to journalArticle

Isa, SI, Kawaguchi, T, Teramukai, S, Minato, K, Ohsaki, Y, Shibata, K, Yonei, T, Hayashibara, K, Fukushima, M, Kawahara, M, Furuse, K & Mack, P 2009, 'Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: Results from JMTO LC 0004', Journal of Thoracic Oncology, vol. 4, no. 9, pp. 1104-1110. https://doi.org/10.1097/JTO.0b013e3181ae2844
Isa, Shun Ichi ; Kawaguchi, Tomoya ; Teramukai, Satoshi ; Minato, Koichi ; Ohsaki, Yoshinobu ; Shibata, Kazuhiko ; Yonei, Toshirou ; Hayashibara, Kenji ; Fukushima, Masanori ; Kawahara, Masaaki ; Furuse, Kiyoyuki ; Mack, Philip. / Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer : Results from JMTO LC 0004. In: Journal of Thoracic Oncology. 2009 ; Vol. 4, No. 9. pp. 1104-1110.
@article{4568a86d978648bf98a3943e1e3c547d,
title = "Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: Results from JMTO LC 0004",
abstract = "BACKGROUND: The Japan-Multinational Trial Organization (JMTO) lung cancer (LC) 0003 was a prospective randomized phase III trial investigating advanced non-small cell lung cancer comparing paclitaxel (P) plus carboplatin (C) versus vinorelbine (V), gemcitabine (G) followed by docetaxel (D). This trial was conducted with Southwest Oncology Group (SWOG) 0003 using a common arm of PC. An analysis of SWOG 0003 samples showed that low osteopontin (OPN) plasma levels were highly prognostic for a better outcome. We performed an independent investigation to validate these results using samples from Japanese patients enrolled in the JMTO LC 0004, a correlative study associated with JMTO LC 0003. METHODS: A total of 20 ml of blood was collected before treatment from patients enrolled in JMTO LC 0003. Serum concentrations of OPN and basic fibroblast growth factor (bFGF) were measured by enzyme-linked immunosorbent assay. Effects of OPN and bFGF levels on tumor response, progression-free survival (PFS), and overall survival (OS) were examined. RESULTS: Seventy-one samples were obtained, including 32 specimens from the PC arm and 39 from the VGD arm. There were no significant relationships between either OPN or bFGF levels with patient characteristics. In an analysis of clinical outcome, low OPN levels correlated with better OS and progression-free survival (hazard ratio [HR] = 0.57; 95{\%} confidence interval [CI], 0.33-0.97; p = 0.037, HR = 0.42; 95{\%} CI, 0.25-0.70; p = 0.001, respectively) and high bFGF levels correlated with better OS (HR = 0.53; 95{\%} CI, 0.31-0.90; p = 0.018). CONCLUSION: Consistent with the findings from SWOG 0003, low OPN serum levels were significantly associated with a favorable prognosis in the JMTO LC 0004. Additionally, high bFGF levels were associated with improved survival.",
keywords = "BFGF, Correlative study, Non-small cell lung cancer, Osteopontin",
author = "Isa, {Shun Ichi} and Tomoya Kawaguchi and Satoshi Teramukai and Koichi Minato and Yoshinobu Ohsaki and Kazuhiko Shibata and Toshirou Yonei and Kenji Hayashibara and Masanori Fukushima and Masaaki Kawahara and Kiyoyuki Furuse and Philip Mack",
year = "2009",
month = "9",
doi = "10.1097/JTO.0b013e3181ae2844",
language = "English (US)",
volume = "4",
pages = "1104--1110",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "9",

}

TY - JOUR

T1 - Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer

T2 - Results from JMTO LC 0004

AU - Isa, Shun Ichi

AU - Kawaguchi, Tomoya

AU - Teramukai, Satoshi

AU - Minato, Koichi

AU - Ohsaki, Yoshinobu

AU - Shibata, Kazuhiko

AU - Yonei, Toshirou

AU - Hayashibara, Kenji

AU - Fukushima, Masanori

AU - Kawahara, Masaaki

AU - Furuse, Kiyoyuki

AU - Mack, Philip

PY - 2009/9

Y1 - 2009/9

N2 - BACKGROUND: The Japan-Multinational Trial Organization (JMTO) lung cancer (LC) 0003 was a prospective randomized phase III trial investigating advanced non-small cell lung cancer comparing paclitaxel (P) plus carboplatin (C) versus vinorelbine (V), gemcitabine (G) followed by docetaxel (D). This trial was conducted with Southwest Oncology Group (SWOG) 0003 using a common arm of PC. An analysis of SWOG 0003 samples showed that low osteopontin (OPN) plasma levels were highly prognostic for a better outcome. We performed an independent investigation to validate these results using samples from Japanese patients enrolled in the JMTO LC 0004, a correlative study associated with JMTO LC 0003. METHODS: A total of 20 ml of blood was collected before treatment from patients enrolled in JMTO LC 0003. Serum concentrations of OPN and basic fibroblast growth factor (bFGF) were measured by enzyme-linked immunosorbent assay. Effects of OPN and bFGF levels on tumor response, progression-free survival (PFS), and overall survival (OS) were examined. RESULTS: Seventy-one samples were obtained, including 32 specimens from the PC arm and 39 from the VGD arm. There were no significant relationships between either OPN or bFGF levels with patient characteristics. In an analysis of clinical outcome, low OPN levels correlated with better OS and progression-free survival (hazard ratio [HR] = 0.57; 95% confidence interval [CI], 0.33-0.97; p = 0.037, HR = 0.42; 95% CI, 0.25-0.70; p = 0.001, respectively) and high bFGF levels correlated with better OS (HR = 0.53; 95% CI, 0.31-0.90; p = 0.018). CONCLUSION: Consistent with the findings from SWOG 0003, low OPN serum levels were significantly associated with a favorable prognosis in the JMTO LC 0004. Additionally, high bFGF levels were associated with improved survival.

AB - BACKGROUND: The Japan-Multinational Trial Organization (JMTO) lung cancer (LC) 0003 was a prospective randomized phase III trial investigating advanced non-small cell lung cancer comparing paclitaxel (P) plus carboplatin (C) versus vinorelbine (V), gemcitabine (G) followed by docetaxel (D). This trial was conducted with Southwest Oncology Group (SWOG) 0003 using a common arm of PC. An analysis of SWOG 0003 samples showed that low osteopontin (OPN) plasma levels were highly prognostic for a better outcome. We performed an independent investigation to validate these results using samples from Japanese patients enrolled in the JMTO LC 0004, a correlative study associated with JMTO LC 0003. METHODS: A total of 20 ml of blood was collected before treatment from patients enrolled in JMTO LC 0003. Serum concentrations of OPN and basic fibroblast growth factor (bFGF) were measured by enzyme-linked immunosorbent assay. Effects of OPN and bFGF levels on tumor response, progression-free survival (PFS), and overall survival (OS) were examined. RESULTS: Seventy-one samples were obtained, including 32 specimens from the PC arm and 39 from the VGD arm. There were no significant relationships between either OPN or bFGF levels with patient characteristics. In an analysis of clinical outcome, low OPN levels correlated with better OS and progression-free survival (hazard ratio [HR] = 0.57; 95% confidence interval [CI], 0.33-0.97; p = 0.037, HR = 0.42; 95% CI, 0.25-0.70; p = 0.001, respectively) and high bFGF levels correlated with better OS (HR = 0.53; 95% CI, 0.31-0.90; p = 0.018). CONCLUSION: Consistent with the findings from SWOG 0003, low OPN serum levels were significantly associated with a favorable prognosis in the JMTO LC 0004. Additionally, high bFGF levels were associated with improved survival.

KW - BFGF

KW - Correlative study

KW - Non-small cell lung cancer

KW - Osteopontin

UR - http://www.scopus.com/inward/record.url?scp=69549097610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549097610&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181ae2844

DO - 10.1097/JTO.0b013e3181ae2844

M3 - Article

VL - 4

SP - 1104

EP - 1110

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 9

ER -